ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

Inhibition of the extracellular signal-regulated kinases ERK1 and ERK2 (ERK1/2) offers a promising therapeutic strategy in cancers harboring activated RAS/RAF/MEK/ERK signaling pathways. Here, we describe an orally bioavailable and selective ERK1/2 inhibitor, ASN007, currently in clinical developmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Portelinha, Ana, Thompson, Scott, Smith, Roger A., Da Silva Ferreira, Mariana, Asgari, Zahra, Knezevic, Andrea, Seshan, Venkatraman, de Stanchina, Elisa, Gupta, Sandeep, Denis, Louis, Younes, Anas, Reddy, Sanjeeva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324497/
https://www.ncbi.nlm.nih.gov/pubmed/34337566
http://dx.doi.org/10.1016/j.xcrm.2021.100350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324497/
https://www.ncbi.nlm.nih.gov/pubmed/34337566
http://dx.doi.org/10.1016/j.xcrm.2021.100350

Ejemplares similares